Plain-English translation of NCT05231655 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →The EVIDENT study is designed to help doctors personalize cancer treatment by testing your tumor sample against various cancer drugs outside your body, in a laboratory setting. Researchers will measure how your specific tumor responds to different treatments and use this information to predict which drugs are most likely to work for you. This approach aims to help doctors choose the most effective treatment before you begin your standard cancer care.
Currently, doctors often cannot predict whether a specific cancer drug will work for a particular patient until after treatment has started. This study exists to see if testing a patient's tumor against drugs in the laboratory can predict treatment success ahead of time, potentially helping doctors make smarter treatment choices from the beginning.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will donate a small sample of tumor tissue that is already being removed during your scheduled surgery or biopsy, plus a 9-milliliter blood sample. The research team will test your tumor sample against various cancer drugs in a laboratory to see how your cancer responds to each one. You will continue receiving your standard cancer treatment as planned, and researchers will track how well your treatment works and compare those real-world results to what the laboratory testing predicted.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom